Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

被引：40

作者：

Ye, Xing-Nong ^{[1
,2
,3
]}

Zhou, Xin-Ping ^{[1
,2
]}

Wei, Ju-Ying ^{[1
,2
]}

Xu, Gai-Xiang ^{[1
]}

Li, Ying ^{[1
]}

Mao, Li-Ping ^{[1
]}

Huang, Jian ^{[1
,3
]}

Ren, Yan-Ling ^{[1
,2
]}

Mei, Chen ^{[1
,2
]}

Wang, Jing-Han ^{[1
]}

Lou, Yin-Jun ^{[1
]}

Ma, Li-Ya ^{[1
]}

Yu, Wen-Juan ^{[1
]}

Ye, Li ^{[1
,2
]}

Xie, Li-Li ^{[1
,2
]}

Luo, Yin-Wan ^{[1
,2
]}

Hu, Chao ^{[1
,2
]}

Niu, Lin-Mei ^{[1
,2
]}

Dou, Min-Hua ^{[1
,2
]}

Jin, Jie ^{[1
]}

Tong, Hong-Yan ^{[1
,2
,3
]}

机构：

[1] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Inst Hematol,Dept Hematol, Hangzhou 310003, Zhejiang, Peoples R China

[2] Zhejiang Univ, Coll Med, Affiliated Hosp 1, MDS Ctr, Hangzhou 310003, Zhejiang, Peoples R China

[3] Zhejiang Univ, Coll Med, Affiliated Hosp 4, Dept Hematol, Hangzhou 310003, Zhejiang, Peoples R China

来源：

LEUKEMIA & LYMPHOMA | 2016年 / 57卷 / 06期

关键词：

Acute myeloid leukemia; cytarabine; decitabine; idarubicin; myelodysplastic syndrome; DNA METHYLATION CHANGES; MYELODYSPLASTIC SYNDROMES; ACUTE-LEUKEMIA; 5-AZA-2'-DEOXYCYTIDINE; AML; MALIGNANCIES; COMBINATION; THERAPY; PHASE-1;

D O I：

10.3109/10428194.2015.1091931

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Decitabine (DAC) is commonly used for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Previous studies have indicated DAC sequentially combined with idarubicin was an effective treatment for myeloid neoplasms. Therefore, a clinical study was conducted of the sequential combination of DAC followed by low-dose idarubicin/cytarabine in high-risk myeloid neoplasms. A total of 30 patients with a diagnosis of high-risk MDS, AML evolving from MDS or relapsed/refractory AML were enrolled in the study. DAC was administered 20mg/m(2) daily for 3 consecutive days. Idarubicin (3mg/m(2)/day) was administered 24 h after the last administration of DAC for 5-7 consecutive days, combined with cytarabine (30mg/m(2)/day) for 7-14 days. The overall complete remission rate was 66.67%. The results demonstrate that epigenetic priming with decitabine followed by low-dose idarubicin/ytarabine has an increased anti-leukemia effect compared to traditional chemotherapy in high-risk myeloid neoplasms.

引用

页码：1311 / 1318

页数：8

共 10 条

[1] Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial
Tong, Hongyan
Zhou, Xinping
Mei, Chen
Zhang, Jin
Lu, Ying
Lan, Jianping
Lin, Shengyun
Zhuang, Yuefeng
Kuang, Yuemin
Ren, Yanling
Ma, Liya
Wei, Juying
Ye, Li
Xu, Weilai
Li, Kongfei
Lu, Chenxi
Jin, Jie
BLOOD, 2019, 134
[2] Effect of low-dose cytarabine and aclarubicin in combination with decitabine on the outcome of patients with high-risk myelodysplastic syndromes
Qian, S.
Duan, L.
Zhu, Y.
Hong, M.
Zhang, R.
Zhang, S.
Liu, P.
Lu, H.
Wu, H.
Qiu, H.
Li, J.
LEUKEMIA RESEARCH, 2013, 37 : S152 - S153
[3] Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial
Zhou, Xinping
Mei, Chen
Zhang, Jin
Lu, Ying
Lan, Jianping
Lin, Shengyun
Zhang, Yuefeng
Kuang, Yuemin
Ren, Yanling
Ma, Liya
Wei, Juying
Ye, Li
Xu, Weilai
Li, Kongfei
Lu, Chenxi
Jin, Jie
Tong, Hongyan
HEMATOLOGICAL ONCOLOGY, 2020, 38 (04) : 531 - 540
[4] A phase II study with decitabine, low-dose cytarabine and G-CSF priming in high-risk myelodysplastic syndromes, refractory/relapsed acute myelogenous leukemia or acute myeloid leukemia in patients with significant comorbidities
Butera, J.
Winer, E.
Wang, C.
Castillo, J. J.
Thomas, A. G.
Safran, H.
Mega, A. E.
Colvin, G. A.
Rathore, B.
Quesenberry, P. J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[5] Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS
Lingyun Wu
Xiao Li
Jiying Su
Qi He
Xi Zhang
Chunkang Chang
Quan Pu
Journal of Cancer Research and Clinical Oncology, 2011, 137 : 1563 - 1569
[6] Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS
Wu, Lingyun
Li, Xiao
Su, Jiying
He, Qi
Zhang, Xi
Chang, Chunkang
Pu, Quan
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (10) : 1563 - 1569
[7] PHASE IB STUDY OF PF-04449913, A HEDGEHOG (HH) INHIBITOR, IN COMBINATION WITH LOW-DOSE CYTARABINE OR INTENSIVE CHEMOTHERAPY, IN ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
Cortes, J.
O'Connell, A.
Shaik, M. N.
Cesari, R.
Abbattista, A.
Woolfson, A.
Pollyea, D.
Savona, M.
HAEMATOLOGICA, 2014, 99 : 33 - 33
[8] Which conditioning regimen is more effective for high-risk patients with acute myeloid leukaemia/myelodysplastic syndrome: comparing Low-dose decitabine combined with modified BUCY with modified BUCY followed by allogeneic stem cell transplantation
Cao, J.
Shi, X.
Ge, L.
Sun, A.
Zhu, X.
Qiu, H.
Jin, Z.
Miao, M.
Fu, C.
Ma, X.
Chen, F.
Xue, S.
Han, Y.
Xue, M.
Mao, X.
Wu, D.
Tang, X.
BONE MARROW TRANSPLANTATION, 2016, 51 : S443 - S443
[9] Hematopoietic cell transplantation (HCT) after low-dose, total body irradiation-based regimen increased leukemia-free survival (LFS) in elderly patients with cytogenetic high-risk AML compared to chemotherapy (OSHO 97 study)
Niederwieser, D.
Becker, C.
Krahl, R.
Al-Ali, H.
Lange, T.
Gerhardt, A.
Schulze, A.
Haehling, D.
Schulze, M.
Freund, M.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[10] A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Mawad, Raya
Gooley, Ted A.
Rajendran, Joseph G.
Fisher, Darrell R.
Gopal, Ajay K.
Deeg, H. Joachim
Shields, Andrew
Green, Damian J.
Maloney, David G.
Sandmaier, Brenda M.
Storb, Rainer
Appelbaum, Frederick R.
Press, Oliver W.
Pagel, John M.
BLOOD, 2012, 120 (21)

← 1 →